BCG Solution

BIOLOGICAL7 trials

Sponsors

Cancer Research Campaign Clinical Trials Centre, Northwestern University, SWOG Cancer Research Network, Fred Hutchinson Cancer Center, Mayo Clinic

Conditions

Bladder CancerBladder Urothelial Carcinoma In SituNon-Muscle Invasive Bladder CarcinomaRecurrent Bladder CarcinomaRecurrent Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder CarcinomaStage 0 Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8

Phase 1

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

CompletedNCT02808143

Northwestern UniversityRecurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma +1

Start: 2017-02-10End: 2022-08-05Updated: 2024-06-26

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

RecruitingNCT06704191

Mayo ClinicNon-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8 +1

Start: 2025-04-21End: 2026-12-31Target: 40Updated: 2026-03-30

Phase 2

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

CompletedNCT04496219

Fred Hutchinson Cancer CenterBladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8 +3

Start: 2021-01-22End: 2022-08-23Updated: 2024-01-02

Phase 3

Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer

Cancer Research Campaign Clinical Trials CentreBladder Cancer

Start: 2009-10-31Target: 242Updated: 2013-08-12

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Active, not recruitingNCT03091660

SWOG Cancer Research NetworkStage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma

Start: 2017-02-24End: 2026-06-15Updated: 2026-03-23

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

RecruitingNCT07000084

Alliance for Clinical Trials in OncologyRecurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8

Start: 2025-07-17End: 2028-12-05Target: 330Updated: 2026-03-04

Phase 4

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

RecruitingNCT07474519

Ohio State University Comprehensive Cancer CenterNon-Muscle Invasive Bladder Carcinoma

Start: 2026-02-26End: 2027-12-31Target: 40Updated: 2026-03-16

Related Papers

Phase I/II randomized clinical trial of in-clinic acupuncture prior to BCG in patients with high-risk non-muscle invasive bladder cancer.

Journal of Clinical Oncology2023-06-01

Abstracts of the 32nd Annual Meeting of the Italian Society of Uro-Oncology (SIUrO).

Anticancer Research2022-10-01

First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin.

2022-08-2346 citations

Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer

BMJ Open2019-07-0110 citations

Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.

2018-09-28101 citations

PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL

The Journal of Urology2017-04-01